Clearing the Air on Residual Solvents - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Clearing the Air on Residual Solvents
USP 9467: Residual Solvents will take effect on July 1, 2008. But does the industry understand these specifications—and is it prepared?

Pharmaceutical Technology

Next steps

Implementation for USP ‹467› was pushed back from July 1, 2007 to July 1, 2008 to allow the industry time to prepare. But even so, analysts worry it may not be enough time. "The regulations have been changed so much and it's been so drawn out that I've got a feeling that a lot of people are behind on this and they are going to be in scramble mode real soon," predicts Schumacher.

FDA plans to issue a Federal Register notice that would clarify when compliance with the USP ‹467› specifications should be reported. A draft is in the works and is currently undergoing the approval process. For products that are already marketed under an NDA or ANDA, manufacturers would report their compliance with USP ‹467› in the next annual report. "I don't think we will require them to include a lot of analytical detail in the annual report," says Ouderkirk. "For example, they may have developed methodologies to comply with ‹467›, and rather than having supplements filed we're just looking to an annual report for them to notify us that they are compliant. We are trying to avoid triggering a lot of supplements from the industry." New NDAs should take ‹467› requirements into consideration. "If I were filing something today, I would want to note that I am complying with ‹467› no later than July 1," says Ouderkirk.

Other organizations also are planning to help clarify the lingering concerns about methods, applications, and changes brought about by USP ‹467›. At its annual scientific meeting in September, USP hosted a track section solely on the issue of residual solvents, and additional training sessions are in the works. Several pharmaceutical laboratories are also planning and sponsoring events and offer their expertise on validated methodologies. These efforts are timely and, apparently, in great need. "I would say it's really about a 50–50 mix of pharmaceutical companies that are fully on board with what is going on here, with 50% that are behind the 8 ball and not really understanding what their responsibility is going to be with this. From a client perspective it seems like some folks haven't kept up with what's going on as to how this has changed," says Emig.


1. Lancaster Laboratories, internal publication on USP ‹467›, available at


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here